We are completing the commercial drug product manufacturing and anticipate commercial drug supply of SKYCLARYS to be available in the second quarter of 2023. Conference Call Information Reata’s ...

Elevation of Aminotransferases: Treatment with SKYCLARYS can cause an elevation in hepatic transaminases (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]). The incidence of ...

Please provide your email address to receive an email when new articles are posted on . Reata Pharmaceuticals announced that Skyclarys is now commercially available for patients older than 16 years ...

With a spring approval in hand, Reata Pharmaceuticals has been waiting patiently to launch its first commercial product, Skyclarys. Now, after an impurity problem stalled the rare disease med’s debut, ...

CAMBRIDGE, Mass., Dec. 15, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended ...

A Plano biotech firm is turning regulatory approval of its first commercial drug into an even bigger deal. Massachusetts-based Biogen Inc. announced Friday that it's buying Reata Pharmaceuticals in a ...

After getting a green light from the European Commission, Biogen’s Skyclarys is the first approved medicine for the inherited neurological disease Friedreich’s ataxia (FA) in the EU. Skyclarys ...

PLANO, Texas--(BUSINESS WIRE)-- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a biopharmaceutical ...

Elevation of Aminotransferases: Treatment with SKYCLARYS can cause an elevation in hepatic transaminases (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]). The incidence of ...

Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a biopharmaceutical company focused on developing and commercializing novel therapies for patients with ...